Prognostic value of ubiquitin E2 UBE2W and its correlation with tumor-infiltrating immune cells in breast cancer.
Breast Neoplasms
/ immunology
DNA Mismatch Repair
/ genetics
Databases, Factual
Female
Gene Expression
Gene Expression Profiling
Genes, BRCA1
Genes, BRCA2
Humans
Lymphocytes, Tumor-Infiltrating
Methyltransferases
/ metabolism
Mutation
Neoplasms
/ metabolism
Prognosis
Tumor Microenvironment
/ immunology
Ubiquitin-Conjugating Enzymes
/ genetics
Ubiquitination
Breast cancer
Endocrine therapy resistance
Prognosis
Tumor immune environment
UBE2W
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
30 Apr 2021
30 Apr 2021
Historique:
received:
05
01
2021
accepted:
20
04
2021
entrez:
1
5
2021
pubmed:
2
5
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Ubiquitin-conjugating enzyme E2W (UBE2W) is a protein-coding gene that has an important role in ubiquitination and may be vital in the repair of DNA damage. However, studies on the prognostic value of UBE2W and its correlation with tumor-infiltrating immune cells in multiple cancers have not been addressed. We investigated UBE2W expression in the Oncomine database, the Tumor Immune Estimation Resource (TIMER), TNMplot database. Then, the clinical prognostic value of UBE2W was analyzed via online public databases. Meanwhile, we explored the correlation between UBE2W and DNA repair associate genes expression and DNA methyltransferase expression by TIMER and Gene Expression Profiling Interactive Analysis (GEPIA). By using the same method, the correlation between UBE2W and tumor-infiltrating immune cells was explored. Genomic Profiles of UBE2W in breast cancer (BRCA) were accessed in cBioPortal (v3.5.0). Functional proteins associated network was analyzed by STRING database (v11.0). UBE2W was abnormally expressed and significantly correlated with mismatch repair (MMR) gene mutation levels, DNA methyltransferase, and BRCA1/2 expression in breast cancer. High expression of UBE2W may promote the tumor immunosuppression and metastasis, induce endocrine therapy resistance and deteriorate outcomes of patients with breast cancer. These findings suggest that UBE2W could be a potential biomarker of prognosis and tumor-infiltrating immune cells. Besides, RBX1 may be a new E3 that was regulated by UBE2W. Ubiquitin E2 UBE2W is a potential prognostic biomarker and is correlated with immune infiltration in BRCA.
Sections du résumé
BACKGROUND
BACKGROUND
Ubiquitin-conjugating enzyme E2W (UBE2W) is a protein-coding gene that has an important role in ubiquitination and may be vital in the repair of DNA damage. However, studies on the prognostic value of UBE2W and its correlation with tumor-infiltrating immune cells in multiple cancers have not been addressed.
METHODS
METHODS
We investigated UBE2W expression in the Oncomine database, the Tumor Immune Estimation Resource (TIMER), TNMplot database. Then, the clinical prognostic value of UBE2W was analyzed via online public databases. Meanwhile, we explored the correlation between UBE2W and DNA repair associate genes expression and DNA methyltransferase expression by TIMER and Gene Expression Profiling Interactive Analysis (GEPIA). By using the same method, the correlation between UBE2W and tumor-infiltrating immune cells was explored. Genomic Profiles of UBE2W in breast cancer (BRCA) were accessed in cBioPortal (v3.5.0). Functional proteins associated network was analyzed by STRING database (v11.0).
RESULTS
RESULTS
UBE2W was abnormally expressed and significantly correlated with mismatch repair (MMR) gene mutation levels, DNA methyltransferase, and BRCA1/2 expression in breast cancer. High expression of UBE2W may promote the tumor immunosuppression and metastasis, induce endocrine therapy resistance and deteriorate outcomes of patients with breast cancer. These findings suggest that UBE2W could be a potential biomarker of prognosis and tumor-infiltrating immune cells. Besides, RBX1 may be a new E3 that was regulated by UBE2W.
CONCLUSIONS
CONCLUSIONS
Ubiquitin E2 UBE2W is a potential prognostic biomarker and is correlated with immune infiltration in BRCA.
Identifiants
pubmed: 33931024
doi: 10.1186/s12885-021-08234-4
pii: 10.1186/s12885-021-08234-4
pmc: PMC8086329
doi:
Substances chimiques
Methyltransferases
EC 2.1.1.-
UBE2W protein, human
EC 2.3.2.23
Ubiquitin-Conjugating Enzymes
EC 2.3.2.23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
479Références
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Breast Cancer Res Treat. 2014 Jul;146(1):211-20
pubmed: 24839032
Cancer Sci. 2004 Nov;95(11):866-71
pubmed: 15546503
Sci Rep. 2016 May 04;6:25208
pubmed: 27143649
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nat Rev Clin Oncol. 2010 Dec;7(12):718-24
pubmed: 20956981
Cancer Treat Rev. 2016 Nov;50:68-81
pubmed: 27643748
Curr Opin Cell Biol. 2009 Dec;21(6):878-84
pubmed: 19850458
Nature. 2019 Mar;567(7748):399-404
pubmed: 30867590
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Nat Struct Mol Biol. 2007 Oct;14(10):941-8
pubmed: 17873885
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Annu Rev Microbiol. 2003;57:579-608
pubmed: 14527292
Nat Rev Cancer. 2006 Oct;6(10):776-88
pubmed: 16990855
Trends Cell Biol. 2014 Jun;24(6):352-9
pubmed: 24457024
BMC Med Genomics. 2009 Apr 24;2:18
pubmed: 19393097
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Drug Discov Today. 2020 Sep 16;:
pubmed: 32947046
Biochem Pharmacol. 2017 Apr 1;129:1-13
pubmed: 27956110
Biochim Biophys Acta. 2008 Dec;1782(12):800-8
pubmed: 18619533
Neoplasia. 2007 Feb;9(2):166-80
pubmed: 17356713
Drug Discov Today. 2016 Jul;21(7):1181-8
pubmed: 27233379
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807717
Surg Oncol. 2016 Sep;25(3):147-51
pubmed: 27566015
Trends Mol Med. 2019 May;25(5):428-443
pubmed: 30898473
Mol Cell. 2008 Dec 26;32(6):767-77
pubmed: 19111657
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Sci Rep. 2016 May 17;6:26178
pubmed: 27185577
Cancer Res. 2010 Feb 15;70(4):1314-22
pubmed: 20145137
Nucleic Acids Res. 2019 Jan 8;47(D1):D721-D728
pubmed: 30289549
Biochim Biophys Acta. 2008 Dec;1782(12):775-84
pubmed: 18778769
Mol Cell. 2011 Aug 19;43(4):599-612
pubmed: 21855799
Mol Cell Proteomics. 2015 Mar;14(3):499-509
pubmed: 25540389
Clin Breast Cancer. 2018 Apr;18(2):184-188
pubmed: 29325860
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Neurobiol Dis. 2018 Jan;109(Pt A):127-136
pubmed: 28986324
Nat Rev Mol Cell Biol. 2006 May;7(5):335-46
pubmed: 16612326
Genome Biol. 2016 Aug 22;17(1):174
pubmed: 27549193
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
J Natl Cancer Inst. 2016 Jul 05;108(11):
pubmed: 27381626
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Discov. 2017 Oct;7(10):1168-1183
pubmed: 28801307
Oncoimmunology. 2020 Apr 14;9(1):1746148
pubmed: 32363114
Gene. 2019 Feb 15;685:24-31
pubmed: 30359738
Front Biosci. 2006 May 01;11:1500-7
pubmed: 16368532
Mol Cells. 2011 Feb;31(2):113-22
pubmed: 21229326
Int J Cancer. 2019 Dec 1;145(11):3140-3151
pubmed: 31020993
Andrologia. 2020 Feb;52(1):e13474
pubmed: 31710394
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
Lancet Oncol. 2010 Apr;11(4):383-90
pubmed: 20359664
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Biochem J. 2013 Jul 1;453(1):137-45
pubmed: 23560854